Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116258 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Mélanie Dos Santos und 22 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, UNICANCER, Centre François Baclesse, Caen, France; Department of Medical Oncology, UNICANCER, Centre François Baclesse,…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Novartis Pharma GmbH, Novartis, French National Cancer Institute.
Abstract (Originalsprache)
PURPOSE: Perioperative chemotherapy with FLOT is a standard of care for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. This trial evaluated the anti-PD-1 monoclonal antibody spartalizumab combined with FLOT as perioperative treatment for resectable patients. PATIENTS AND METHODS: GASPAR is a multicenter, single-arm, Simon two-stage phase 2 trial. Patients with untreated localized gastric or GEJ adenocarcinoma considered resectable (≥ cT2 or cN+) received 4 pre- and post-operative cycles of FLOT and 2 pre- and post-operative cycles of spartalizumab. The main endpoint was the rate of pathological complete regression (pCR) according to the Becker criteria, requiring 67 patients (H0/H1 =10/23 %, α=5 %, β=20 %). RESULTS: Overall, 68 patients were included: men (78 %), median age 63 years [range 31-79], cT3 51 %, GEJ 60 %, cN+ 58 %. Treatment was started in 67 patients. Delayed FLOT administration for toxicity and dose reduction concerned 14 (21 %) and 28 (42 %) patients, respectively. Surgery was R0 in 62 (95 %) of the patients operated on. Among 64 patients assessable for efficacy, pCR was observed in 20 patients (31 %), and major pathological response in 12 patients (19 %), meaning a major response rate of 50 %. Five patients developed grade 3 immune-mediated adverse events. One death related to pneumocystis occurred. Severe post-surgery complications occurred in 15 patients (23 %). After a median follow-up of 30 months [range 4-42], OS and DFS at 2 years were 86 % [77.8-94.9] and 77.5 % [68.1-88.2], respectively. CONCLUSIONS: Spartalizumab combined with FLOT shows high efficacy as perioperative treatment in patients with resectable gastric cancer, and an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04736485.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Department, UNICANCER, Centre François Baclesse, Caen, France; Department of Medical Oncology, UNICANCER, Centre François Baclesse, Caen, France. Electronic address: m.dossantos@baclesse.unicancer.fr.
- Clinical Research Department, UNICANCER, Centre François Baclesse, Caen, France.
- University of Lille, CNRS, INSERM, CHU Lille, Department of Digestive and Oncological Surgery, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
- Digestive Medical Oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- Department of Medicine, Institut Bergonié, 229 cours de l'Argonne, Bordeaux, France.
- CHU Reims, Université de Reims Champagne-Ardenne, Reims, France.
Förderung
- Novartis Pharma GmbH
- Novartis
- French National Cancer Institute
Zitieren
APA
Dos Santos, M., Lequesne, J., Piessen, G., Leconte, A., Guimbaud, R., Pernot, S., Bouche, O., Hiret, S., Soularue, E., Tougeron, D., Dahan, L., Le Sourd, S., Borg, C., Samalin, E., Corbinais, S., Parzy, A., Guilloit, J. M., Varatharajah, S., Brachet, P. E., …, & Clarisse, B. (2026). Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116258
Vancouver
Dos Santos M, Lequesne J, Piessen G, Leconte A, Guimbaud R, Pernot S, et al. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116258
BibTeX
@article{DosSantos2026,
author = {Dos Santos, Mélanie and Lequesne, Justine and Piessen, Guillaume and Leconte, Alexandra and Guimbaud, Rosine and Pernot, Simon and Bouche, Olivier and Hiret, Sandrine and Soularue, Emilie and Tougeron, David and Dahan, Laetitia and Le Sourd, Samuel and Borg, Christophe and Samalin, Emmanuelle and Corbinais, Stéphane and Parzy, Aurélie and Guilloit, Jean-Marc and Varatharajah, Sharmini and Brachet, Pierre-Emmanuel and Dorbeau, Marine and Galais, Marie-Pierre and Desgrippes, Romain and Clarisse, Bénédicte},
title = {Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116258}
}
EUVIMED